Butler, Kevin and Le Foll, Bernard (2019) Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review. Frontiers in Psychiatry, 10. ISSN 1664-0640
Document
-
13762.pdf - Published Version
Available under License Creative Commons Attribution.
Abstract
Abstract
Substance use disorders are chronic, relapsing, and harmful conditions characterized by executive dysfunction. While there are currently no approved pharmacotherapy options for stimulant and cannabis use disorders, there are several evidence-based options available to help reduce symptoms during detoxification and aid long-term cessation for those with tobacco, alcohol and opioid use disorders. While these medication options have shown clinical efficacy, less is known regarding their potential to enhance executive function. This narrative review aims to provide a brief overview of research that has investigated whether commonly used pharmacotherapies for these substance use disorders (nicotine, bupropion, varenicline, disulfiram, acamprosate, nalmefene, naltrexone, methadone, buprenorphine, and lofexidine) effect three core executive function components (working memory, inhibitory control and cognitive flexibility). While pharmacotherapy-induced enhancement of executive function may improve cessation outcomes in dependent populations, there are limited and inconsistent findings regarding the effects of these medications on executive function. We discuss possible reasons for the mixed findings and suggest some future avenues of work that may enhance the understanding of addiction pharmacotherapy and cognitive training interventions and lead to improved patient outcomes.
| Item Type: | Article |
|---|---|
| Depositing User: | Leah Maughan |
| URI: | https://sure.sunderland.ac.uk/id/eprint/13762 |
Further Details
More Information
Identifiers
Users with ORCIDS
Catalogue record
Contributors
University Divisions
Actions (login required)
Download Statistics
Downloads per month over past year


Dimensions
Dimensions